Gan & Lee(SH:603087) Cai Jing Wang·2026-01-16 05:26Core Viewpoint - Recently, Ganli Pharmaceutical (603087) announced the approval of its insulin glargine injection and pre-filled pen by the Ethiopian National Food and Drug Administration, marking a significant opportunity for the company in the Ethiopian market [1] Company Summary - The insulin glargine product is designed for diabetes patients, characterized by long-acting and stable blood sugar control, requiring subcutaneous injection once daily with a duration of action lasting up to 24 hours [1] - As of September 30, 2025, the company has invested a total of 936 million RMB in research and development for the insulin glargine project [1] Industry Summary - According to the International Diabetes Federation, the estimated number of diabetes patients aged 20-79 in Ethiopia is approximately 2.3 million, with a diabetes prevalence rate of 3.6% in 2024 [1] - While the approval of the drug registration provides a sales opportunity in the Ethiopian market, the company faces uncertainties related to market demand fluctuations, policy environment changes, and exchange rate volatility [1]